Get the Stockscreener App
4.02
3.13%
-0.13
After Hours:
4.04
0.02
+0.50%
Achieve Life Sciences Inc stock is traded at $4.02, with a volume of 781.75K.
It is down -3.13% in the last 24 hours and up +38.62% over the past month.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
See More
Previous Close:
$4.15
Open:
$4.15
24h Volume:
781.75K
Relative Volume:
0.80
Market Cap:
$214.02M
Revenue:
-
Net Income/Loss:
$-54.65M
P/E Ratio:
-3.1047
EPS:
-1.2948
Net Cash Flow:
$-49.47M
1W Performance:
-21.18%
1M Performance:
+38.62%
6M Performance:
-19.60%
1Y Performance:
+67.50%
1-Day Range:
$3.935
$4.19
1-Week Range:
$3.935
$5.30
52-Week Range:
$2.00
$6.025
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
4.02 | 214.02M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Nov-25-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
View All
Achieve Life Sciences Inc Stock (ACHV) Latest News
Paradigm discloses 9.2% stake in Achieve Life (NASDAQ: ACHV) - Stock Titan
TPG takes 12.6% Achieve Life Sciences (ACHV) stake via $25M structured deal - Stock Titan
TPG-affiliated holders disclose Achieve Life Sciences (NASDAQ: ACHV) shares and warrants position - Stock Titan
Achieve Life Sciences (ACHV) director files Form 3 reporting zero share ownership - Stock Titan
Frazier Life Sciences (ACHV) holds 6.5% stake; warrants disclosed - Stock Titan
Venrock entities disclose 5.2% stake in Achieve Life (ACHV) after April placement - Stock Titan
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Buy" by Brokerages - MarketBeat
Achieve Life Sciences announces proposed public offering; shares down nearly 13% - MSN
Achieve Life Sciences announces private placement of up to $354M - MSN
Achieve Life Sciences (NASDAQ:ACHV) Stock Rating Upgraded by Canaccord Genuity Group - MarketBeat
Achieve Life Sciences: Up To $354 Million Private Placement Funds Cytisinicline Development And Commercialization - Pulse 2.0
Achieve Life Sciences (ACHV) grants CEO large PRSU, option and RSU awards - Stock Titan
ACHIEVE LIFE SCIENCES (ACHV) CEO files Form 3 reporting zero beneficial ownership - Stock Titan
ACHV Initiates Coverage On Canaccord Genuity -- Rating Set to Bu - GuruFocus
Canaccord Genuity Initiates Coverage on Achieve Life Sciences With Buy Rating, $13 Price Target - marketscreener.com
Achieve Life Sciences flags FDA observations while pushing launch to 2027 for smoking cessation med - MSN
Bothell biotech names new CEO, looks to raise $354 million - The Business Journals
Achieve Life Sciences to Host Meetings During the J.P. Morgan He - GuruFocus
Achieve Life Sciences secures $354M financing deal By Investing.com - Investing.com Australia
Achieve Life Sciences names new CEO, adds board members By Investing.com - Investing.com Australia
Achieve Life Sciences Secures Up to $354 Million Private Placement to Advance Cytisinicline for Smoking and Vaping Cessation - Minichart
Achieve Life Sciences (ACHV) Secures $354M Through Private Place - GuruFocus
Achieve Life Sciences Raises Capital, Appoints New CEO - TipRanks
$354M funding and new CEO reshape Achieve Life Sciences (NASDAQ: ACHV) - Stock Titan
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - Stocktwits
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Achieve Life Sciences names new CEO, adds board members - Investing.com
Achieve Life Sciences secures $354M financing deal - Investing.com
ACHV Reiterates by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
ACHV Stock Gains Focus As Cytisinicline Data And NDA Timeline Firm Up - timothysykes.com
Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors - The Manila Times
Achieve Life Sciences Announces Up to $354 Million Private Placement - The Manila Times
Achieve Life Sciences, Inc. appoints Andrew D Goldberg as chief executive officer - Traders Union
Achieve Life Sciences Appoints New Healthcare Leaders to Board and Secures Up to $354 Million Financing for Cytisinicline Development - Moomoo
Achieve Life Sciences Secures $354 Million Financing to Advance Cytisinicline Development for Nicotine Dependence - Quiver Quantitative
Achieve Life Sciences Announces Appointment of Andrew D. - GlobeNewswire
Achieve Life Sciences, Inc. Announces Chief Executive Officer Changes - marketscreener.com
Achieve Life Sciences' (ACHV) Buy Rating Reiterated at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Achieve Life Sciences stock By Investing.com - Investing.com Canada
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions - Sahm
Achieve Life Sciences shifts cytisinicline production to U.S. By Investing.com - Investing.com Australia
Achieve Life Sciences Shares Fall After FDA Inspection Finds Violations - marketscreener.com
Achieve Life Sciences shifts cytisinicline production to U.S. - Investing.com
Achieve Life Sciences Announces Operational Progress - GlobeNewswire
ACHV Forecast, Price Target & Analyst Ratings | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Aug Big Picture: Is Achieve Life Sciences Inc stock forming a triangle patternInsider Selling & Real-Time Volume Spike Alerts - baoquankhu1.vn
Nicotine dependence therapy research advances as Achieve Life Sciences, Inc. pushes for new solutions - Traders Union
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2025 earnings call transcript - MSN
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.01%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):